ProQR Therapeutics
PRQR
42 hedge funds and large institutions have $134M invested in ProQR Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 7 closing their positions.
167% more call options, than puts
Call options by funds: $8K | Put options by funds: $3K
1.94% more ownership
Funds ownership: 53.92% → 55.87% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 44 → 42 (-2)
24% less capital invested
Capital invested by funds: $177M → $134M (-$42.8M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$730K |
| 2 |
RI
RTW Investments
New York
|
+$368K |
| 3 |
JP Morgan Chase
New York
|
+$356K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$128K |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$66.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$2.75M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.86M |
| 3 |
Morgan Stanley
New York
|
-$914K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$764K |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$626K |
PRQR Hedge Fund Activity: Q3 2020 in Review
42 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2020, worth a combined $134M — down 24% from $177M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRQR and 5 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was Fidelity International, adding an estimated $730K. The largest seller was Kerrisdale Advisers, exiting entirely with an estimated $2.75M sold.
- 42 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2020, down from 44 in Q2 2020.
- Funds reported $134M of ProQR Therapeutics stock for Q3 2020, down 24% quarter-over-quarter.
- 5 funds opened new ProQR Therapeutics positions in Q3 2020 and 7 closed out, a net change of -2 holders.
- The largest ProQR Therapeutics buyer in Q3 2020 was Fidelity International, an estimated $730K added.
- The largest ProQR Therapeutics seller in Q3 2020 was Kerrisdale Advisers, an estimated $2.75M sold.
Based on aggregated 13F filings for Q3 2020.